CoChat

Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study

Open access
Ma, Ling-Zhi, Tan, Lan, Bi, Yan-Lin, Shen, Xue-Ning, Xu, Wei, Ma, Ya-Hui, Li, Hong-Qi, Dong, Qiang, Yu, Jin-Tai · 2020 · Molecular Neurodegeneration
Cited by 84

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Background: Loss of function of triggering receptor expressed on myeloid cell 2 (TREM2), a key receptor selectively expressed by microglia in the brain, contributes to the development of Alzheimer’s disease (AD). Whether TREM2 levels are pathologically altered during the preclinical phase, and whether cerebrospinal fluid (CSF) soluble TREM2 protein (sTREM2) has a relationship with major pathological processes including Aβ and tau deposition are still unclear. Methods: According to the NIA-AA criteria, 659 cognitively normal participants from the Chinese Alzheimer’s Biomarker and LifestylE (CABLE) cohort were divided into four groups, stage 0 (normal Aβ 1–42, T-tau and P-tau), stage 1 (low Aβ 1–42, normal T-tau and P-tau), stage 2 (low Aβ 1–42 and high T-tau or P-tau), and suspected non-AD pathology (SNAP) (normal Aβ 1–42 and high T-tau or P-tau), to examine changes of CSF sTREM2 in the preclinical AD. Biomarker cut-off was based on the assumption that one-third of adults with normal cognition have AD pathology. Results: The level of CSF sTREM2 in the stage 1 decreased compared with the stage 0 (P < 0.001), and then increased in the stage 2 (P = 0.008). SNAP individuals also had significantly increased CSF sTREM2 (P < 0.001). Results of multiple linear regressions also showed positive correlations of CSF sTREM2 with Aβ 1–42 (β = 0.192, P < 0.001), T-tau (β = 0.215, P < 0.001) and P-tau (β = 0.123, P < 0.001). Conclusion: CSF sTREM2 levels are dynamic in preclinical AD. Aβ pathology is associated with a decrease in CSF sTREM2 in the absence of tau deposition and neurodegeneration. However, tau pathology and neurodegeneration are associated with an increase in CSF sTREM2.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13024-020-00374-8

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 84

Metadata

Authors
Ma, L.-Z., Tan, L., Bi, Y.-L., Shen, X.-N., Xu, W., Ma, Y.-H., Li, H.-Q., Dong, Q., & Yu, J.-T.
Venue
Molecular Neurodegeneration
Published
2020-04-10
Volume
15
Issue
1
Pages
25-25
ISSN
1750-1326 (ISSN-L)
OpenAlex
W3015842246
Cited by
84
References
25
FWCI
7.82
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study. https://app.cochat.ai/papers/10.1186/s13024-020-00374-8
The paper
Ma, L.-Z., Tan, L., Bi, Y.-L., Shen, X.-N., Xu, W., Ma, Y.-H., Li, H.-Q., Dong, Q., & Yu, J.-T. (2020). Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-020-00374-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.